BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19211183)

  • 1. Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma.
    Andrade VC; Vettore AL; Regis Silva MR; Felix RS; Almeida MS; de Carvalho F; Zago MA; Caballero OL; Simpson AJ; Colleoni GW
    Exp Hematol; 2009 Apr; 37(4):446-9. PubMed ID: 19211183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
    Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
    Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Quantitative analysis of human herpes virus type 8 and expression of its genes in patients with multiple myeloma].
    Dong Y; Zhu P; Ma M
    Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(20):1230-3. PubMed ID: 11825524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and expression of CT45 in Hodgkin's lymphoma.
    Heidebrecht HJ; Claviez A; Kruse ML; Pollmann M; Buck F; Harder S; Tiemann M; Dörffel W; Parwaresch R
    Clin Cancer Res; 2006 Aug; 12(16):4804-11. PubMed ID: 16914565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues.
    Bièche I; Narjoz C; Asselah T; Vacher S; Marcellin P; Lidereau R; Beaune P; de Waziers I
    Pharmacogenet Genomics; 2007 Sep; 17(9):731-42. PubMed ID: 17700362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
    Pabst C; Zustin J; Jacobsen F; Luetkens T; Kröger N; Schilling G; Bokemeyer C; Sauter G; Atanackovic D; Marx A
    Exp Mol Pathol; 2010 Oct; 89(2):175-81. PubMed ID: 20621094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of PRAME gene in multiple myeloma].
    Abramenko IV; Belous NI; Kriachok IA; Chumak AA; Aksenova EV; Lisovskaia EV; Misiurin AV
    Ter Arkh; 2004; 76(7):77-81. PubMed ID: 15379133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.
    Andrade VC; Vettore AL; Felix RS; Almeida MS; Carvalho F; Oliveira JS; Chauffaille ML; Andriolo A; Caballero OL; Zago MA; Colleoni GW
    Cancer Immun; 2008 Feb; 8():2. PubMed ID: 18237105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer.
    Buergy D; Fuchs T; Kambakamba P; Mudduluru G; Maurer G; Post S; Tang Y; Nakada MT; Yan L; Allgayer H
    Cancer; 2009 Oct; 115(20):4667-78. PubMed ID: 19569245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.
    de Carvalho F; Alves VL; Braga WM; Xavier CV; Colleoni GW
    Cancer Immunol Immunother; 2013 Jan; 62(1):191-5. PubMed ID: 23180015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer.
    Chen YT; Hsu M; Lee P; Shin SJ; Mhawech-Fauceglia P; Odunsi K; Altorki NK; Song CJ; Jin BQ; Simpson AJ; Old LJ
    Int J Cancer; 2009 Jun; 124(12):2893-8. PubMed ID: 19296537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
    Scavelli C; Nico B; Cirulli T; Ria R; Di Pietro G; Mangieri D; Bacigalupo A; Mangialardi G; Coluccia AM; Caravita T; Molica S; Ribatti D; Dammacco F; Vacca A
    Oncogene; 2008 Jan; 27(5):663-74. PubMed ID: 17667938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
    Martín P; Santón A; García-Cosío M; Bellas C
    Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.
    Armellini A; Sarasquete ME; García-Sanz R; Chillón MC; Balanzategui A; Alcoceba M; Fuertes M; López R; Hernández JM; Fernández-Calvo J; Sierra M; Megido M; Orfão A; Gutiérrez NC; González M; San Miguel JF
    Br J Haematol; 2008 Apr; 141(2):212-5. PubMed ID: 18353163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma.
    Atamaniuk J; Gleiss A; Porpaczy E; Kainz B; Grunt TW; Raderer M; Hilgarth B; Drach J; Ludwig H; Gisslinger H; Jaeger U; Gaiger A
    Eur J Clin Invest; 2012 Sep; 42(9):953-60. PubMed ID: 22591013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 expression level and clinical factors in multiple myeloma.
    Hatta Y; Takeuchi J; Saitoh T; Itoh T; Ishizuka H; Iriyama N; Miyajima T; Kaneita Y; Saiki M; Yasukawa K; Yasukawa R; Kura Y; Nishinarita S; Sawada U; Horie T
    J Exp Clin Cancer Res; 2005 Dec; 24(4):595-9. PubMed ID: 16471322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.
    Dakshinamurthy AG; Ramesar R; Goldberg P; Blackburn JM
    Biotechnol J; 2008 Nov; 3(11):1417-23. PubMed ID: 18956367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.
    Rendtlew Danielsen JM; Knudsen LM; Dahl IM; Lodahl M; Rasmussen T
    Br J Haematol; 2007 Sep; 138(6):756-60. PubMed ID: 17760807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of bone marrow fibrosis in multiple myeloma.
    Subramanian R; Basu D; Dutta TK
    Pathology; 2007 Oct; 39(5):512-5. PubMed ID: 17886102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.